Your browser doesn't support javascript.
loading
The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
Huynh, My-My; Pambid, Mary Rose; Jayanthan, Aarthi; Dorr, Andrew; Los, Gerrit; Dunn, Sandra E.
Affiliation
  • Huynh MM; Pre-clinical R&D, Phoenix Molecular Designs , Vancouver, BC, Canada.
  • Pambid MR; Pre-clinical R&D, Phoenix Molecular Designs , Vancouver, BC, Canada.
  • Jayanthan A; Pre-clinical R&D, Phoenix Molecular Designs , Vancouver, BC, Canada.
  • Dorr A; Clinical Operations, Phoenix Molecular Designs , San Diego, CA, USA.
  • Los G; Clinical Operations, Phoenix Molecular Designs , San Diego, CA, USA.
  • Dunn SE; Pre-clinical R&D, Phoenix Molecular Designs , Vancouver, BC, Canada.
Expert Opin Investig Drugs ; 29(11): 1199-1208, 2020 Nov.
Article in En | MEDLINE | ID: mdl-32869671
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Molecular Targeted Therapy / Triple Negative Breast Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2020 Type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Molecular Targeted Therapy / Triple Negative Breast Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2020 Type: Article Affiliation country: Canada